Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group-Reference-Cited by-同舟云学术

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Published:2021-05-29 Issue:6 Volume:149 Page:1322-1331
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Hofheinz Ralf‐Dieter¹^ORCID,Hegewisch‐Becker Susanne²,Kunzmann Volker³,Thuss‐Patience Peter⁴,Fuchs Martin⁵,Homann Nils⁶,Graeven Ullrich⁷,Schulte Nadine¹,Merx Kirsten¹,Pohl Michael⁸,Held Swantje⁹,Keller Ralph¹⁰,Tannapfel Andrea¹¹,Al‐Batran Salah‐Eddin¹²

Affiliation:

1. Interdisziplinäres Tumorzentrum, Universitätsmedizin Mannheim Universität Heidelberg Mannheim Germany

2. Hämatologisch‐Onkologische Praxis Eppendorf Hamburg Germany

3. Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany

4. Medizinische Klinik mit Schwerpunkt Hämatologie Onkologie und Tumorimmunologie, Charité, Universitätsmedizin Berlin Berlin Germany

5. Klinikum Bogenhausen, Klinik für Gastroenterologie Hepatologie, Gastroenterologische Onkologie München München Germany

6. Medizinische Klinik II Wolfsburg Wolfsburg Germany

7. Klinik für Hämatologie Onkologie und Gastroenterologie, Kliniken Mariahilf Mönchengladbach Germany

8. Medizinische Universitätsklinik Bochum Knappschaftskrankenhaus Bochum Germany

9. ClinAssess GmbH Leverkusen Germany

10. AIO Studien gGmbH Berlin Germany

11. Institut für Pathologie der Ruhr‐Universität Bochum Bochum Germany

12. Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest UCT‐University Cancer Center Frankfurt am Main Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33696

Reference22 articles.

1. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

2. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

3. Perspectives of HER2-targeting in gastric and esophageal cancer

4. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment

5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapie des Magenkarzinoms und AEG – wie reihen sich klinische AIO-Studien in die Therapielandschaft ein?;Die Onkologie;2024-09-02

2. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

3. SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023);Clinical and Translational Oncology;2024-07-18

4. ESTUDO COMPARATIVO DOS DIFERENTES TRATAMENTOS INFUSIONAIS PARA O CÂNCER DE ESTÔMAGO: UMA REVISÃO INTEGRATIVA;Revista Contemporânea;2024-04-25

5. Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice;International Journal of Molecular Sciences;2024-03-30